Drug · CHEMBL657
DIPHENHYDRAMINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. DIPHENHYDRAMINE. Drugs and targets, record CHEMBL657. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL657
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| HRH1 | Histamine H1 receptor | Histamine H1 receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/3269 |
Source ChEMBL
Diseases42
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 42Source Open Targets
See all 42 diseasesTrials107
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01280591 | Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain | Phase 3 | 712 | 2014-06-17 | diphenhydramine | Its name | ClinicalTrials.gov |
| NCT02655354 | A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity | 635 | 2021-07-02 | diphenhydramine | Its name | ClinicalTrials.gov | |
| NCT00682734 | Metoclopramide for Migraine: A Dose Finding Study | Phase 3 | 349 | 2012-12-31 | diphenhydramine | Its name | ClinicalTrials.gov |
| NCT00937924 | Adjunct Sedatives in Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures | Phase 4 | 304 | 2024-02-26 | diphenhydramine | Its name | ClinicalTrials.gov |
| NCT00475306 | The Montefiore Metoclopramide Study | Phase 4 | 289 | 2012-12-31 | diphenhydramine | Its name | ClinicalTrials.gov |
| NCT01929226 | Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers | Phase 1 | 280 | 2019-04-08 | diphenhydramine | Its name | ClinicalTrials.gov |
| NCT02229539 | Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy | Phase 3 | 275 | 2017-04-10 | diphenhydramine | Its name | ClinicalTrials.gov |
| NCT01495858 | Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain | Phase 3 | 267 | 2014-06-17 | diphenhydramine | Its name | ClinicalTrials.gov |
| NCT02935699 | Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria | Phase 3 | 262 | 2019-11-27 | diphenhydramine | Its name | ClinicalTrials.gov |
| NCT01825941 | Diphenhydramine for Acute Migraine | Phase 4 | 208 | 2018-06-08 | diphenhydramine | Its name | ClinicalTrials.gov |
1 to 10 of 107
See all 107 trialsComparisons in its trials64
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Intervention vs Usual Care: deaths from any cause | 6 of 265 | 3 of 370 | 635 | NCT02655354 | Trial comparisons |
| Intervention vs Usual Care: serious adverse events | 15 of 265 | 13 of 370 | 635 | NCT02655354 | Trial comparisons |
| ETI-204 vs Placebo: Number of Participants With Anti-ETI-204 Antibodies | 2 of 210 | 0 of 70 | 280 | NCT01929226 | Trial comparisons |
| ETI-204 vs Placebo: Number of Participants Who Experienced Adverse Events | 88 of 210 | 27 of 70 | 280 | NCT01929226 | Trial comparisons |
| ETI-204 vs Placebo: deaths from any cause | 0 of 210 | 0 of 70 | 280 | NCT01929226 | Trial comparisons |
| ETI-204 vs Placebo: serious adverse events | 0 of 210 | 1 of 70 | 280 | NCT01929226 | Trial comparisons |
| Test Drug vs Control: Number of Patients Who Needed to Return to Treatment Center | 7 of 127 | 19 of 135 | 262 | NCT02935699 | Trial comparisons |
| Test Drug vs Control: deaths from any cause | 0 of 127 | 0 of 135 | 262 | NCT02935699 | Trial comparisons |
| Test Drug vs Control: serious adverse events | 0 of 127 | 1 of 135 | 262 | NCT02935699 | Trial comparisons |
| Metoclopramide + Diphenhydramine vs Metoclopramide + Placebo: deaths from any cause | 0 of 104 | 0 of 104 | 208 | NCT01825941 | Trial comparisons |
1 to 10 of 64
See all 64 comparisons in its trialsPapers from its trials63
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials10
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Symbol Coding | 4 | 0 | ConductCognition |
| Category Fluency | 1 | 0 | ConductCognition |
| Choice Reaction Time | 1 | 1 | ConductCognition |
| Digit Span Test | 1 | 1 | ConductCognition |
| Paired Associate Learning | 1 | 1 | ConductCognition |
| Psychomotor Vigilance Task | 1 | 0 | ConductCognition |
| Rapid Visual Information Processing | 1 | 1 | ConductCognition |
| Stroop Color-Word Test | 1 | 0 | ConductCognition |
| Tower Planning | 1 | 0 | ConductCognition |
| Verbal Fluency | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL657
GET https://conductscience.org/api/drugs/v1/CHEMBL657/diseases?page=2